IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
IRVINE, California - Edwards Lifesciences (NYSE:EW) has received U.S. Food and Drug Administration approval for its SAPIEN M3 mitral valve replacement system, marking the first transcatheter therapy ...
Please provide your email address to receive an email when new articles are posted on . A transseptal mitral valve replacement system was approved for patients unsuitable for surgery or transcatheter ...
The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...
1 Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou, China 2 Department of Geriatric Cardiology, The First ...
Transcatheter edge-to-edge mitral and tricuspid valve repair (M-TEER, T-TEER) have emerged as meaningful treatment modalities among patients at high surgical risk suffering from valvular heart disease ...
Doctors at Novant Health recently completed a minimally invasive surgery on a tricky heart valve for the first time, marking a significant advancement in heart care for Brunswick County residents. The ...
Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...
Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for severe mitral regurgitation are more than twice as likely to die or be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback